Objectives: Concerns on climate change are leading to the renaissance of wood burning and particulate exposures. Levo glucosan is used as a marker of woodsmoke in air and urine. Objectives: Contribution of data on urinary excretion of levo glucosan, to improve biomonitoring and source apportionment of woodsmoke. Materials and Methods: 1, 3, 5, and 7 hours after 5 mg of levoglucosan had been administered orally, urinary excretion was measured by HPLC and mass spectrometry. Results: After oral intake, urine concentrations increased rapidly, reached highest values after 3 hours, and after 7 hours approximately 70% of the administered dose was excreted. Conclusions: Urinary levoglucosan may be used for biomoni toring of woodsmoke exposure on the same day.
INTRODUCTION
Levoglucosan is considered to be a specific marker of woodsmoke used in environmental monitoring of source-specific air pollutants [1, 2] . Nowadays, rising oil prices and threats of climate change have brought about a revival of "good old" wood stoves which often are rather old than good [3] . This has also brought renewed interest into markers of woodsmoke exposure. It is well established that aerosol from incineration sources is of special health relevance as an air pollutant. Only few studies have attempted to estimate the relative impact of aerosols from wood burning, mostly due to the lack of available data [4, 5] . This situation could be improved by either intensifying ambient monitoring of markers or by applying specific markers of exposure in biomoni toring. Levoglucosan has also been proposed as a bio monitoring marker [6] [7] [8] , but little has been known until now about its kinetics in humans. Animal stud ies indicate that most of the substance is excreted fast and unchanged [7] , which would indicate low toxicity.
Nevertheless, Miyakawa et al. [9] report some evidence of a carcinogenic effect in mice. In spite of this infor mation, we decided to study the kinetics of orally ad used as nebulizer, curtain and collision cell gas. Multiple reaction monitoring (MRM) mode was used for quantita tive determination with the following MS/MS transitions: Levoglucosan (160.9 to 112.9 and 160.9 to 70.8 for qualita tive confirmation), Levoglucosan-13C6 (166.9 to 104.8). Table 1 shows the findings of the urine analyses. Even in the morning samples that had been collected before the administration of levoglucosan the substance was de tected at 5-6 μg/ml (HM = 5.8; MN = 5.2). This is in ac cordance with the findings in pooled samples of morning urine collected from 10 randomly selected Viennese fe male participants of a biomonitoring study (unpublished data). Furthermore, this is confirmed by a recent study which stated that the levoglucosan background level is present due to dietary influences [10] . After the oral in take, urine concentrations increased rapidly and reached the highest values after 3 hours (Figure 1 ). After 7 hours, approximately 70% of the administered dose was excret ed in urine (Figure 2 ). The logarithm of masses excreted after 3, 5 and 7 hours showed a nearly linear decrease with an estimated halflife of levoglucosan in urine bet ween 4 and 5 hours. 
RESULTS

MATERIALS AND METHODS
We hypothesized that orally administered levoglucosan is excreted unchanged, in a short time, via urine. To test this hypothesis, the two volunteers provided early morning urine on July 20th, a fine day in summer with no apparent woodsmoke present during the previous days. Crystalline levoglucosan weighing 20.62 mg was dissolved in 4 ml of water. At 8:45 a.m. both volunteers drank 1 ml of this solu tion each, containing 5.155 mg of levoglucosan (60,65 μg/kg in HM and 68,73 μg/kg in MN). Urine samples were pro vided 1, 3, 5, and 7 hours afterwards. Urine volume was measured and the samples were delivered to the laboratory at the Umweltbundesamt GmbH on the same day. Levoglucosan (99%) was purchased from Aldrich (Vien na, Austria), acetonitrile, water (HPLC grade) and carbon labeled levoglucosan from LGC Promochem (Wesel, Ger many). The samples were spiked with the isotopically labeled sur rogate standard and diluted 1:10 in HPLC water. The analysis of levoglucosan was performed on a HP1200 HPLC (Agilent Technologies, Vienna, Austria) consisting of a membrane degasser, a binary highpressure pump, an automatic sampler and a column heater, connected to a 4000 QTrap mass spectrometer (Applied Biosytems, Darmstadt, Germany). Chromatographic separation was achieved by coupling two 150×2.0 mm Shodex ODP2HP 2D columns (Phenomenex, Aschaffenburg, Germany) with 5 μm particle size at the temperature of 25°C. The eluents were acetonitrile (A) and HPLC water (B). Gra dient elution was used starting with 1% A at 0 min, held for 1 min, increased to 20% A at 7 min, held for 2 min, increased to 70% A at 10 min, held for 2 min, reduced to 1% A at 13 min. The Total Run Time was 45 min. The injection volume was 10 μl. Ionization was performed in the negative electrospray mode.
The source was operated at the temperature of 400°C and the voltage of 4500 V. Nitrogen was provided by a nitrogen generator (CMC instruments, Eschborn, Germany) and an increase of the urinary levoglucosan level within 2 hours of caramel consumption and no consistent increase after exposure to woodsmoke, suspecting a stronger influence of dietary levoglucosan. In our experiment, all sweets (in particular caramelized ones) and inhalation of woodsmoke (except that from low urban background in summer) had been avoided. Our findings show that levoglucosan con centrations not only depend on the intake, but also depend strongly on the timing of the samples due to a short half time of the substance. To establish levoglucosan as a valu able biomarker of individual exposure more research on temporal and individual variability is needed. On the other hand, on a population level we have recently found (unpub lished data) that levoglucosan in urine can reliably predict exposure to polycyclic aromatic hydrocarbons.
DISCUSSION
Recently, the analysis of levoglucosan in air and urine has been used more frequently as a marker of exposure to woodsmoke [6, 8] . To our knowledge, this is the first study following oral administration in humans. Animal stu dies [7] indicate a short half-life with fast excretion of the unchanged substance. We were able to show that the same is true for human metabolism. While Neitzel et al. [8] reported an association between le voglucosan and CO exposure of firemen fighting wood fires, Hinwood et al. [6] found no increase in levoglucosan con centration in firemen after a training fire. Both studies did not control for ambient exposure. Bergauff et al. [10] found
Abbreviations as in Table 1 . Fig. 1 . Excretion of levoglucosan in urine after the intake of 5155 μg
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Fig. 2. Levoglucosan in urine -cumulative excretion
